BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21514416)

  • 1. Tissue microarray cytometry reveals positive impact of homeodomain interacting protein kinase 2 in colon cancer survival irrespective of p53 function.
    Soubeyran I; Mahouche I; Grigoletto A; Leste-Lasserre T; Drutel G; Rey C; Pedeboscq S; Blanchard F; Brouste V; Sabourin JC; Bécouarn Y; Reiffers J; Ichas F; De Giorgi F
    Am J Pathol; 2011 May; 178(5):1986-98. PubMed ID: 21514416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
    Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
    Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
    Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
    Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear factor erythroid 2 (NF-E2) p45-related factor 2 interferes with homeodomain-interacting protein kinase 2/p53 activity to impair solid tumors chemosensitivity.
    D'Orazi G; Garufi A; Cirone M
    IUBMB Life; 2020 Aug; 72(8):1634-1639. PubMed ID: 32593231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains.
    Möller A; Sirma H; Hofmann TG; Rueffer S; Klimczak E; Dröge W; Will H; Schmitz ML
    Cancer Res; 2003 Aug; 63(15):4310-4. PubMed ID: 12907596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell cycle proteins predict recurrence in stage II and III colon cancer.
    Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer.
    Sarasqueta AF; Forte G; Corver WE; de Miranda NF; Ruano D; van Eijk R; Oosting J; Tollenaar RA; van Wezel T; Morreau H
    BMC Cancer; 2013 Jun; 13():277. PubMed ID: 23739040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
    Di Stefano V; Soddu S; Sacchi A; D'Orazi G
    Oncogene; 2005 Aug; 24(35):5431-42. PubMed ID: 15897882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIPK2 Overexpression and Its Prognostic Role in Human Papillomavirus-Positive Tonsillar Squamous Cell Carcinoma.
    Kwon MJ; Kang SY; Nam ES; Cho SJ; Rho YS
    Biomed Res Int; 2017; 2017():1056427. PubMed ID: 28607924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.
    Hofmann TG; Möller A; Sirma H; Zentgraf H; Taya Y; Dröge W; Will H; Schmitz ML
    Nat Cell Biol; 2002 Jan; 4(1):1-10. PubMed ID: 11740489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis.
    Puca R; Nardinocchi L; Starace G; Rechavi G; Sacchi A; Givol D; D'Orazi G
    Free Radic Biol Med; 2010 May; 48(10):1338-46. PubMed ID: 20171273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Tyrosine Kinase c-Abl Promotes Homeodomain-interacting Protein Kinase 2 (HIPK2) Accumulation and Activation in Response to DNA Damage.
    Reuven N; Adler J; Porat Z; Polonio-Vallon T; Hofmann TG; Shaul Y
    J Biol Chem; 2015 Jul; 290(27):16478-88. PubMed ID: 25944899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.
    D'Orazi G; Cecchinelli B; Bruno T; Manni I; Higashimoto Y; Saito S; Gostissa M; Coen S; Marchetti A; Del Sal G; Piaggio G; Fanciulli M; Appella E; Soddu S
    Nat Cell Biol; 2002 Jan; 4(1):11-9. PubMed ID: 11780126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Counteracting MDM2-induced HIPK2 downregulation restores HIPK2/p53 apoptotic signaling in cancer cells.
    Nardinocchi L; Puca R; Givol D; D'Orazi G
    FEBS Lett; 2010 Oct; 584(19):4253-8. PubMed ID: 20849851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis.
    Cecchinelli B; Lavra L; Rinaldo C; Iacovelli S; Gurtner A; Gasbarri A; Ulivieri A; Del Prete F; Trovato M; Piaggio G; Bartolazzi A; Soddu S; Sciacchitano S
    Mol Cell Biol; 2006 Jun; 26(12):4746-57. PubMed ID: 16738336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas.
    Lavra L; Rinaldo C; Ulivieri A; Luciani E; Fidanza P; Giacomelli L; Bellotti C; Ricci A; Trovato M; Soddu S; Bartolazzi A; Sciacchitano S
    PLoS One; 2011; 6(6):e20665. PubMed ID: 21698151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIPK2-a therapeutical target to be (re)activated for tumor suppression: role in p53 activation and HIF-1α inhibition.
    Nardinocchi L; Puca R; Givol D; D'Orazi G
    Cell Cycle; 2010 Apr; 9(7):1270-5. PubMed ID: 20234185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.
    Sung KS; Lee YA; Kim ET; Lee SR; Ahn JH; Choi CY
    Exp Cell Res; 2011 Apr; 317(7):1060-70. PubMed ID: 21192925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.